BioAge Labs (BIOA) shares slumped 70% pre-bell Monday after the company said late Friday it is terminating a phase 2 trial of its obesity drug candidate following observations of liver transaminitis.
Universe Pharmaceuticals (UPC) shares fell 54% after the company unveiled a $15 million registered direct offering of ordinary shares and warrants.
Radiopharm Theranostics (RADX) shares dropped 25% after Friday's 7% increase.
Palmer Square Capital (PSBD) shares retreated 18% following a 1.3% gain in the previous session.
Forrester Research (FORR) shares were down 17% following a muted session.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.